Cancer Stem Cells and ALDH1A1
Not without controversy, cancer stem cells (CSC) are considered capable of symmetrical or asymmetric self-renewal, resistance to standard chemo-or radio-therapies, less differentiated, and tumorgenic, the latter evident by ability in low numbers to establish tumors in immunodeficient mice. 1, 2 As the failure of current therapies to control cancer can be attributed to their inability to eliminate CSC, there is a critical need to develop strategies that eliminate these "stem cell-like" tumor cells.
Employing the methods of flow cytometry-based studies of hematopoietic and leukemic stem cells, highly enriched populations of tumor cells with "stem cell-like" properties have been isolated from many types of human carcinomas. Most recently, it is based on elevated expression of aldehyde dehydrogenase (ALDH) activity. In combination with DEAB, an inhibitor of the ALDH1A1, -A2, -A3 and ALDH3A1 isoforms, the flow reagent ALDEFLUOR identifies ALDH + cells. 3 Expression of ALDH1A1, which metabolizes genotoxic aldehydes, is critical to the chemoradioresistance of normal stem cells and tumor cells. However, while it is not absolute that all CSC are ALDH + cells, isolated populations of ALDH + tumor cells certainly have characteristics distinct from the remaining tumor cell population.
Identification of ALDH1A1 as a
Shared Tumor Antigen (TA)
In a collaborative study with Dr. Theresa Whiteside, my laboratory identified ALDH1A1 88-96 peptide as a shared CTLdefined human tumor antigen (TA) in squamous cell carcinoma of the head and neck (SCCHN). 4 Given that only one or two exchanges distinguish the peptides encoded by codons 88-96 of the ALDH1/ 3 isoforms, particular attention was paid to ensure that the HLA-A2-restricted CTL were specific for the ALDH1A1 88-96 peptide. Furthermore, ALDH1A1 expression at the protein level correlated with the severity of oral mucosal dysplasia and less differentiated and more aggressive SCCHN lesions. These findings suggested that it might be an early marker for development of SCCHN and an attractive target for immunoprevention as well as therapy of this disease.
Somewhat unappreciated at first, as one became more aware of the roles of ALDH1A1 in retinoic acid metabolism and detoxification of genotoxic aldehydes, its identification as a TA gained our attention. (Fig. 1) . Of the in vivo-based assays performed to show the efficacy of ALDH1A1-specific CTL-based therapy performed in collaboration with Dr. Hui Wang' laboratory, particularly important was adoptive transfer of CTL to mice following surgical removal of primary MDA-MB-231-derived orthotopic xenografts. These mice generally succumb to metastases within two months. Following their surgery, however, treatment of mice with ALDH1A1-specific CTL until all untreated control mice died increased their survival past seven months.
Given that CD34 + hematopoietic stem cells (HSC) express ALDH1A1, 3 starting from our initial study, it has been critical to show that HSC are not recognized by ALDH1A1-specific CTL. To date, there is no indication that HSC, even pretreated with IFNc, are recognized in vitro by ALDH1A1-specific CTL; most likely, because the ALDH1A1 level is lower than in tumor cells. In ancillary mouse experiments, immunization of mice with dendritic cells transfected with aldh1a1 cDNA (mouse ALDH1A1 homolog) induced aldh1a1-reactive T cells and had no overall effect on hematopoiesis using absolute numbers and CD4 + /CD8 + T cell ratios as surrogate markers.
Future Directions
Future research efforts require the use of primary tumors arising in genetically modified mouse models of human cancer to demonstrate efficacy of ALDH1A1-basedactive and passive immunotherapy in eliminating CSC and controlling tumor growth and metastases. However, any type of therapy promotes tumor escape. To minimize this, we are investigating the efficacy of combinatorial strategies to target CSC by combining ALDH1A1-specific CTL with stem cell-signaling pathway inhibitors 9 and antibody-based therapies.
